Samit Hirawat
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer(2019)2,462 cited
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,956 cited
- → PTC124 targets genetic disorders caused by nonsense mutations(2007)1,121 cited
- → Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial(2018)985 cited
- → Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial(2008)387 cited
- → The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy(2009)386 cited
- → PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model(2008)249 cited
- → Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis(2010)240 cited
- → Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers(2007)238 cited
- → PI3K inhibitors as new cancer therapeutics: implications for clinical trial design(2016)230 cited